summari report better-than-expect result
morn manag rais organ revenu growth
outlook retir bottom-end ep outlook rang
full year revenu y/i organ beat
estim consensu driven strong
contribut urolift adj ep y/i beat
estim consensu primarili driven
lower-effect tax rate also time expens
day-adjust organ revenu growth improv rel
prior year quarter key driver continu
take hold sequenti quarter
due time distributor order difficult y/i
comparison compani stack two-year growth
normal level impli us
underli busi continu acceler quarter
reiter outperform rate base
approxim ep estim
adjust estim reflect higher fx
higher organ growth expect cadenc
oper margin expans overal deliv solid
quarter broad base growth meaning contribut
key growth driver urolift rais organ ex-fx
growth outlook mid-point new rang
retir low-end ep guidanc
new rang ex-fx organ
revenu growth outlook impli step-down appear
conserv given strong year-to-d ytd perform ep
growth outlook impli step-up driven tfx
expect continu margin improv fx expect
greater headwind top line versu
ep versu result
adjust estim lower report revenu
number reflect higher fx
headwind increas revenu estim
reflect busi momentum next
year rais ep estim
y/i top-end compani guidanc rang
lower ep estim
reflect appropri ramp oper margin next year
continu page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
continu previou page
day-adjust organ growth y/i well exceed estim
deliv better-than-expect result driven broad base growth segment vascular
access sale ex-fx exceed estim driven strong mid-singl
digit growth cvc central venou cathet well ez-io intraoss access devic product
line low-doubl digit growth picc peripher insert central cathet manag expect
step growth due tougher comp result distributor stock expect
portfolio grow pace go forward intervent access sale ex-fx
shi estim driven legaci portfolio vsi portfolio continu perform
expect estim manta contribut approxim sale quarter appear
gain traction earli limit launch given high percentag repeat order believ
portfolio posit low-doubl digit growth ahead addit upsid manta ramp surgic
sale ex-fx came better estim driven sale ligat
clip surgic instrument expect step-down growth due medic devic steril
issu worth note expect materi impact anesthesia
sale ex-fx in-lin estim driven sale endotrach tube
laryngoscop believ percuv continu show-m product minim
sale product year next intervent urolog sale ex-fx
exceed estim driven strong urolift adopt drove rais full year
segment outlook y/i growth oem sale ex-fx in-lin
estim better manag project despit tough y/i comp final
sale ex-fx estim due declin respiratori
medic devic steril issu expect impact result nearli off-set
extra sell day recent experienc suspens oper third parti steril
partner site ga caus disrupt select product resid surgic oem busi
compani abl off-set impact safeti stock initi estim
headwind sale ep began re-qual steril
cycl area issu aros led closur third-parti facil ga
believ cycl re-valid manag note
clear line slight ga facil may re-activ expect impact
immateri also acknowledg issu remain fluid time pleas see note
date octob med-tech thought medic devic steril issu detail
rais outlook urolift y/i versu urolift gener sale
ahead above-consensu estim repres y/i growth manag
note call sale forc make meaning progress drive physician adopt
urolift system expect train urologist year compani direct-to-consum dtc
program also track well help drive patient awar manag
indic quarter ago low transit custom urolift
expect full convers physician base japan make pre-commerci
invest urolift still track limit market releas revenu ramp
meaning overal urolift adopt appear track well led manag rais
full year segment growth outlook y/i
manta limit market releas progress well note call first month
manta limit market releas gone well product receiv posit physician feedback
notabl final product price strategi tier base volum etc
addit manag note account penetr re-ord rate initi adopt
strong current model manta price repres premium suture-
mediat closur system cost per procedur manag believ devic eas
use time hemostasi lower complic rate continu justifi cost focus
gener posit clinic data manta remaind expect begin full market
releas januari note manta includ compani lrp long-
rang plan like provid upsid meaning uptak begin
percuv re-launch progress appear slow major updat ezpla
commerci note call percuv limit progress per plan
remain show-m product limit releas expect continu end
plan provid addit updat either extend limit market releas full market releas
provid guidanc recal includ approxim contribut
percuv lrp elsewher provid major updat ezpla respect
commerci timelin await updat fda get clear line sight
bla submiss compani submit data fda work addit test
continu next month agre work pediatr studi worth note
includ contribut ezpla lrp includ contribut
oper margin y/i driven y/i improv gross
margin deliv gross margin y/i driven increas sale
volum benefit cost improv program favor sale mix higher margin product
partial off-set tariff deliv adjust oper margin y/i
driven improv gross margin time invest spend volum
leverag report lower effect tax rate prior year level
due discret tax benefit look ahead manag maintain outlook gross margin
oper margin lower outlook effect tax rate
impli growth growth ex-fx prior ep growth vascular compani report secur llc estim incorpor
million except per share data fiscal year end decemb good gross total oper oper interest expens pre-tax incom net minor net incom sharehold fulli dilut dilut ep adj margin sharehold growthrevenu good incom sharehold compani report secur llc estim medic technolog
price target nc
valu approxim ep estim arriv price target
reflect premium peer reflect compani improv organ cc growth profil om
expans improv profil current trade low ratio rel peer
group despit potenti growth acceler provid meaning upsid risk includ
follow core busi may abl deliv state growth goal
new product ramp may fall short expect time distributor order destock may
caus earn stock price volatil depend reimburs environ
continu uptak product may becom unfavor
pois deliv mid-to-high singl digit revenu mid-teen ep growth
peer well fargo large-cap med-tech index believ compani defens
natur posit sustain growth ahead notabl major product util
emerg emerg care set total sale area well-entrench
market posit also certain growth acceler urolift manta percuv repla
could posit deliv profit growth state goal street estim
found headquart wayn pa teleflex incorpor global diversifi medic
devic compani oper multipl end market sell product follow segments-
vascular access intervent surgic anesthesia intervent urolog oem
depend upon one end-market procedur growth given diversifi natur
gener sale repres organ revenu growth y/i
